“Collaborate with scientific experts to keep improving patients’ quality of life by innovating and bringing the best medicines to patients.”
Your role at Institut Roche and brief presentation of your professional background:
I joined Institut Roche in 2024 as a clinical pharmacometrician. My role is to support drug development for pRED (Roche Pharma Research and Early Development), by building mathematical models that describe the time course in the body of drugs and key biomarkers. These models help finding the right dose for the right patients. We describe the pharmacokinetics of a drug in a large population, and link it to safety or efficacy endpoints. With these models, we try to accelerate drug development by predicting as early as possible drug efficacy and safety in the targeted population.
My Focus at Institut Roche:
For immuno-oncology and cardio-vascular projects: develop non-linear fixed effect models to support drug development (population PK models with covariate selection, tumor growth inhibition models, PK-safety and PK-efficacy relationship) in collaboration with the project team members.